AzTrials
AzTrials

Parkinson's DiseasePhase 2NCT00209508

2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD

A Phase 2 study testing GPI 1485 in people with Parkinson's Disease, run by Eisai Inc..

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being treated with a dopamine agonist therapy. Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Parkinson's Disease
What is being tested?
GPI 1485
How many people
200 participants
Where
No sites listed yet
Study dates
Nov 2002to Oct 2005
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and female patients 40 - 80 years of age with a diagnosis of idiopathic PD < 10 years. The diagnosis of idiopathic PD will be based on the medical history, neurologic examination, current response to anti-PD medication(s), and the presence of at least two of the following at the time of diagnosis: resting tremor, bradykinesia, or rigidity.
  • Females must be postmenopausal for >= 12 months, surgically sterile, or agree to use acceptable forms of contraception. A negative serum pregnancy test must be confirmed prior to first dose for women of childbearing potential.
  • Clinical diagnosis of idiopathic mild to moderate PD characterized by a Hoehn and Yahr rating of 1 to 3 in the 'Off' state (measured before the first dose of anti-PD medications on the day of assessment).
  • UPDRS Motor 'Off' rating of 8-30 (measured before the first dose of anti-PD medications on the day of assessment).
  • Mini-Mental Status Examination (MMSE) score of <= 25.
  • Currently treated with an optimized dose of a dopamine agonist (stable dose for >= 1 month prior to randomization and treatment is optimized in the opinion of the Investigator).
  • In the judgment of the Investigator the patient will not require L-Dopa therapy within the 3 months after randomization.
  • Concomitant therapy with amantadine, selegiline, or anticholinergics is permitted, but not required. If the patient is treated with any of these medications the dose of this medication must be judged optimal and stable for > 1 month prior to randomization.

Who cannot join

  • Presence of motor fluctuations including drug-induced dyskinesia, but excluding the pre-dose 'Off' state (prior to the first dose of anti-parkinsonian medication(s) on the day of assessment).
  • History of surgical treatment of PD.
  • Presence of clinical signs consistent with a neurologic disorder other than PD including, but not limited to, progressive supranuclear palsy, multiple system atrophy (Shy-Drager syndrome, olivopontocerebellar degeneration, striatonigral degeneration), corticobasal degeneration, Pick's disease, diffuse Lewy body disease, dementia, schizophrenia, psychosis, or hallucinations.
  • Presence of clinically significant depression as measured by the HAM-D Scale with a score > 16. If the patient is on an antidepressant, the dose must be judged optimal and stable for ³ 1 month prior to randomization.
  • Presence of clinically significant, in the judgment of the Investigator, urinary incontinence, cardiac arrhythmia, or symptomatic orthostatic hypotension.
  • History of seizure disorder or the occurrence of 1 or more seizures within 1 year before screening.
Show all 15Show fewer
  • Any medical disability (e.g., peptic ulcer disease, severe degenerative arthritis, compromised nutritional state) or laboratory abnormality (e.g., serum creatinine > 2.0 mg/dL) that may interfere with the protocol-specified safety and efficacy measurements, present an unacceptable risk to the patient's well-being, or compromise the patient's ability to provide informed consent.
  • Recent history, within the 2 years before screening, of drug or alcohol abuse.
  • History of anaphylaxis.
  • Previous treatment with L-Dopa for > 90 days or treatment with L-Dopa within 30 days prior to the baseline assessment.
  • Treatment within the 3 months before the Baseline SPECT Scan with modafinil.
  • Treatment within the 6 months before screening with neuroleptics, methylphenidate, metoclopramide, cinnarizine, flunarizine, reserpine, alpha methyldopa, amphetamine, or monoamine oxidase-A (MOA-A) inhibitors.
  • Previous exposure to GPI 1485 (previously AMG-474-00).
  • Treatment with an investigational agent within the 30 days before screening or scheduled to receive an investigational agent other than that specified by this protocol during the course of this study.
  • Females that are pregnant, breast feeding, or do not agree to use an acceptable form of contraception.

About this study

Official title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.

This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being treated with a dopamine agonist therapy. Whether the drug is working will be assessed by evaluating clinical endpoints such as UPDRS scores and by evaluating images, obtained by SPECT scan, of brain activity. Participants in the study will be given either placebo or GPI 1485 treatment. The duration of the study is 2-years and patients are required to complete 12 safety visits and 3 SPECT scans. SPECT scans will be taken before, after 1-year, and after 2-years of treatment with GPI 1485. In completing the SPECT scan, patients will be injected with a radioactive investigational drug b-CIT and pictures taken using a Single Photon Emission Computed Tomography (SPECT) camera.

Read the detailed description

In this phase II study, the investigational new drug (not approved by the FDA) GPI 1485 is being assessed for its ability to delay or stop disease progression and improve symptoms in patients with mild to moderate Parkinson's disease (PD). These potential effects of GPI 1485 are based on animal studies in which the drug was shown to both protect nerves from damage and to regrow damaged nerves. Participants in this study will be randomly assigned to receive either GPI 1485 or placebo (inactive pill). GPI 1485 will be supplied as an oral tablet formulation to participants enrolled in the study. Participants randomly assigned to receive GPI 1485 will be required to take four tablets four times a day by mouth. GPI 1485 matching placebo will also be supplied as an oral tablet formulation. Participants randomly assigned to placebo will be required to take four placebo tablets four times a day by mouth. The duration of this study is 24 months which includes 12 clinical visits at one of 21 participating sites and three imaging visits to Molecular NeuroImaging (MNI) in New Haven Connecticut. At MNI, participants will be injected with a radioactive investigational drug b-CIT to obtain images of the activity in the brain with Single Photon Emission Computed Tomography (SPECT). This will evaluate whether GPI 1485 slows or delays the loss of brain activity in patients with mild to moderate PD. During this study you will also have other clinical evaluations including a physical exam, blood work, ECG (tracing of your heart rhythm), and urinalysis. Tests specific to Parkinson's disease will also be performed including: Unified Parkinson's Disease Rating Scale (UPDRS), Dyskinesia Rating Scale, Bilateral finger-tapping test, and Parkinson's Disease Sleep Scale (PDSS). In addition assessments of your health and mood will be done.

Being tested
GPI 1485
Keywords
Parkinson's Disease, SPECT Scanning
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GPI 1485Drug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To evaluate the efficacy of GPI 1485 vs. placebo on the percent change from baseline in [123I]ß-CIT/SPECT striatal uptake over 2 years in patients with idiopathic PD.

Secondary outcomes (7)

  1. To evaluate the efficacy of GPI 1485 vs. placebo in the treatment of symptomatic idiopathic PD patients using the following prespecified clinical measures of greatest interest:

  2. Mean daily L-Dopa Therapy Equivalents

  3. UPDRS ('On')

  4. Measures of sleep

  5. Cognitive function

  6. To evaluate the efficacy of GPI 1485 versus placebo using the following other acceptable measures of clinical assessment.

  7. To evaluate the efficacy of GPI 1485 versus placebo on the percent change from baseline in [123I]ß-CIT/SPECT putamen and caudate uptake over 2 years in patients with idiopathic PD.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2005 (estimated)
  2. Study startNov 2002
  3. Study completionOct 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00209508
Sponsor's protocol ID
0501-0201
Status last verified
Nov 2008
First submitted
13 Sep 2005
Last updated
7 Nov 2008
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GPI 1485 in people with Parkinson's Disease, run by Eisai Inc..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2008. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To evaluate the efficacy of GPI 1485 vs. placebo on the percent change from baseline in [123I]ß-CIT/SPECT striatal uptake over 2 years in patients with idiopathic PD.. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00209508.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2008; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in